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Abstract Drugs availabletotreat asthma have improved considerably over the pastthree decades and understanding 
of the disease process is continually improving. However, the incidence of asthma is increasing and the cause(s) of this 
increase are not yet identified. Asthma is often underdiagnosed and undertreated. Poor compliance with medication is 
also an important consideration in how effective management strategies can be. The aim of current asthma treatment, 
according to the Global Initiative for Asthma (GINA), is to control the disease. However, two surveys, one in Europe and 
the other in the U.S.A. indicate that the objectives of treatment guidelines are not being met. Patients were shown to 
experience high rates of exacerbations and require many doses of reliever medication.There was also a large difference 
between patient and physician perceptions of treatment--this needs to be countered b/improved education for both 
the general public and healthcare professionals. Fo:moterol, which is the only/~2-agonist to possess both fast- and long- 
acting properties, may help to improve patient compliance by allowing a single inhaler to be used for both maintenance 
and as-needed therapy. However, although formote:ol is already widely used as maintenance therap)4, currenttreatment 
guidelines do not include the use of formoterol as first-line reliever medication. Evidence is increasing to support as- 
needed use and a large, randomized effectiveness tud), in 18 000 patients across the world is ongoing to assess the safety 
and efficacy offormoterol as needed in a real-life setting.The results from the Real-Life Effectiveness of Oxis®Turbuha - 
let ® (RELIEF)study should help to establish the position of formoterol as an effective fi rst-line reliever medication and 
ultimately lead to the inclusion offormoterol as needed in treatment guidelines. 
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INTRODUCTION 
Understanding of the pathophysiology of asthma is im- 
proving all the time and more is now known about the 
underlying inflammatory processes that result in symp- 
toms and acute attacks. Although treatment of asthma 
has advanced over the past 30 years due to the availabil- 
ity of drugs to treat symptoms (e.g. short-acting/32-ago- 
nists) and inflammation (e.g. inhaled corticosteroids), the 
prevalence of asthma has increased over the past two 
decades (I,2). Allergen exposure and parental smoking 
have both been identified as risk factors but the impact 
of air pollution has not been proven. 
The Global Initiative for Asthma (GINA) is a project 
conducted in collaboration with the National Heart, 
Lung and Blood Institute and the World Health Organi- 
zation with the aim of helping healthcare professionals to 
reduce asthma prevalence, morbidity and mortality. 
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Although GINA produces guidelines for asthma diagnosis 
and treatment, it is also important not to forget patient 
needs in working towards the optimum treatment strat- 
egy Patients are not so concerned with clinical measures 
such as peak flow measurements or forced expiratory 
volume in I second (FEVi)--for patients, the main aim is 
to have a treatment strategy that allows them to live 
normal lives with minimum interference in everyday ac- 
tivities. 
The GINA treatment guidelines are currently being 
updated, and any changes to current guidelines will be 
based on strong evidence of efficacy, safety, comparison 
with other therapies and cost-effectiveness. As it has 
now been suggested that many meta-analyses have ser- 
ious methodological flaws, it may be better for such evi- 
dence to be obtained from large randomized studies (3). 
Currently, short-acting/~2-agonists are placed as relie- 
ver medication for symptom control. In contrast, fl2-ago- 
nists with long-acting properties, formoterol and 
salmeterol, are recommended only as maintenance ther- 
apy in moderate to severe patients poorly controlled on 
inhaled corticosteroids. Formoterol differs from all 
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other #2-agonists, including salmeterol--it has not only a 
long duration of action but also a fast onset, and is there- 
fore suitable for use as needed as well as in regular ther- 
apy. 
GINA GUIDELINES FOR THE 
TREAT MENT OF ASTHMA 
The GINA guidelines state that the goal of asthma ther- 
apy should be to" eliminate all symptoms, including those 
experienced at night-time; prevent exacerbations and 
minimize need for as-needed #2-agonist therapy; pre- 
vent limitation of activities; minimize side effects from 
treatment; and provide the patient with near normal 
lung function (4). However, asthma prevalence is increas- 
ing, particularly in children, and it is often underdiag- 
nosed and undertreated. Treatment guidelines stress the 
importance of controlling inflammation, in particular 
with inhaled corticosteroids, and emphasis is placed on 
gaining control of symptoms promptly and stepping 
down treatment when control has been achieved. The 
use of long-acting #2-agonists with low-dose inhaled cor- 
ticosteroids is an effective alternative to increasing the 
dose of corticosteroids prescribed for patients with 
moderate persistent asthma (5). 
The Asthma Insights and Reality in Europe (AIRE) 
study was a large survey carried out in seven countries 
across Europe (6). Over 2800 asthmatic adults and chil- 
dren were questioned about their asthma status and 
treatment. Current asthma (defined as physician 
diagnosed with symptoms within the last 12 months) 
was found to be prevalent in 3488 out of 73 880 house- 
holds screened. 
When patients were questioned about their disease 
management, it was clear that treatment of asthma in 
Europe falls well short of the goals for long-term man- 
agement established by GINA. Over one-third of chil- 
dren and half of all the adults surveyed had daytime 
symptoms at least once per week and only 39.5% of chil- 
dren and 55% of adults reported ever having had a lung 
function test performed by their doctor. Other findings 
are summarized inTable I. 
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Patients were classified as having mild intermittent, 
mild persistent, moderate persistent or severe persis- 
tent asthma according to the frequency and severity of 
symptoms reported. When questioned about their dis- 
ease control, patients felt that their asthma was well 
managed and 76.5% of children and 65.9% of adults said 
they had either no symptoms or mild asthma during the 
past 4 weeks. However, some of the patients who felt 
that their disease was either well- or completely-con- 
trolled were actually assessed as having severe persis- 
tent asthma (Fig. I). 
Many factors were felt to contribute to the difference 
between patient perception and the reality of asthma 
control. Not only do patients underestimate the severity 
of their disease, they also overestimate the degree to 
which their asthma is controlled. Patients, thus, accept a 
lower degree of control than is achievable with current 
treatment strategies. Furthermore, this is compounded 
by physicians, as many trust the patients'own perception 
of their disease state and do not monitor the condition 
closely by adequate history taking and performing regu- 
lar lung function tests. 
A similar survey in the U.S.A.--Asthma in America 
(AIA)~cluestioned over 2500 adults and children and 
found similar results (7). Patients were poorly con- 
trolled, with many exacerbations and a high level of lost 
work or school days. Sleep disruption, due to breathing 
problems at least once per week, was reported by 30% 
of patients and 48% said that asthma limits their ability 
to take part in sports or recreation. Other results are 
summarized inTable 2. Even though comprehensive treat- 
ment guidelines are available, many patients and their fa- 
milies suffer to an unnecessary degree due to morbidity 
associated with their asthma. Additionally, 47% of pa- 
tients used their reliever medication daily, including 74% 
of patients with severe persistent and 21% with mild in- 
termittent asthma. According to the guidelines, this level 
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Figure I. Symptom severity index by patient/parent 
classification of asthma control (6), Symptom severity index 
according to frequency and severity of symptoms, SP: 
severe persistent; HOP: moderate persistent; HP: mild persis- 
tent; lv]l: mild intermittent, [Repr-oduced with permission from 
Eur Respir j~ 
of short-acting flz-agonist use is an indicator of poorly 
controlled asthma. 
These surveys signify the importance of better educa- 
tion for asthmatic patients and their primary care physi- 
cians. Without this, optimal treatment cannot be 
achieved and the objectives of the GINA treatment 
guidelines will not be met. Future initiatives by GINA in- 
clude the supervision of World Asthma Day acti- 
vities and development of an asthma practice audit 
and information gateway, with the aim of increasing 
:::::::::::::::::::::: :::::A7%:ofpati~nts:us~drelieve~medicatibndAily :: :::it::::: :: 
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patient awareness of their disease and, thus, improving 
treatment. 
FORMOTEROLmPOSIT ION IN 
CURRENTAND FUTURE GUIDELINES 
Formoterol is widely accepted to have a unique position 
as the only fl2-agonist with both fast- and long-acting 
properties. In current guidelines, fl2-agonists with a 
long-acting profile, including formoterol, are first-choice 
therapies for combination with low-to-moderate dose 
inhaled corticosteroids in moderate to severe asthma; 
data have shown this to be an effective choice, which is 
well tolerated in patients (5). Formoterol is also cur- 
rently used as add-on therapy to high-dose corticoster- 
oids in patients with severe persistent asthma--in 
combination with other drugs--and can decrease the 
need for oral steroids by reducing the number of exacer- 
bations (8). 
Although formoterol is licensed in many countries for 
as-needed therapy in patients already receiving it as 
maintenance therapy, it is not currently included as first- 
line reliever medication in management guidelines. How- 
ever, evidence is increasing to support he use of formo- 
terol in this and other areas of asthma treatment, 
including as-needed use in exercise-induced broncho- 
constriction (EIB) and also for regular use in mild persis- 
tent asthma in addition to low doses of inhaled 
corticosteroids. In the Oxis 'g~ and Pulmicort ~ Turbuha- 
ler 'g' in the Management of Asthma (OPTIMA) study 
the addition of formoterol 4.5 #g twice daily to budeso- 
nide resulted in fewer severe exacerbations and poorly 
controlled days in patients insufficiently controlled on 
budesonide 100 Itg twice daily compared with increasing 
the dose of budesonide to 200#g twice daily (9). 
Formoterol 4.5 #g has been shown to provide more ef- 
fective control, compared with terbutaline 500 itg, when 
used as first-line reliever medication in mild to moderate 
persistent asthma on maintenance therapy with inhaled 
corticosteroids (10). Additionally, in patients with moder- 
ate to severe persistent asthma on regular treatment 
with the combination of inhaled corticosteroids and 
long-acting inhaled fl2-agonists, formoterol has been 
shown to be as good as terbutaline when used as needed 
(11). In patients receiving regular twice-daily treatment 
with formoterol plus additional inhalations as needed, 
superior asthma control was shown in patients with 
moderate to severe asthma compared with salbutamol, 
twice daily plus as needed (12). Furthermore, formoterol 
has been shown to be well tolerated, with side effects si- 
milar in nature and duration to other fl2-agonists 
(13-16). 
In EIB, a number of studies have shown that formoter- 
ol produces adegree of bronchoprotection equivalent to 
terbutaline, but with a much longer duration (17-18). 
Formoterol Turbuhaler ®4.5 gg as needed 
Salbutamol pMD1200 gg as needed 
q (or equivalent dose via DPI) 
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Figure 2. RELIEF study design, pP1DI: pressurized metered 
dose inhaler; DPI: dry powder inhaler. 
Although with continued use it is not clear whether the 
maximum duration of effect, i.e. 12 h, is maintained, for- 
moterol does still provide significant protection, even 
after prolonged use. 
Health economics is also very important in deciding 
which treatment strategy is the most appropriate. Add- 
ing formoterol to inhaled corticosteroid therapy has 
been shown to be a cost-effective approach in the treat- 
ment of moderately asthmatic patients (19). Further- 
more, in the Tattersfield study (10) formoterol used as 
first-line reliever medication has been shown to generate 
cost savings compared with terbutaline, resulting from a 
decrease in the number of severe exacerbations experi- 
enced (20). 
The available evidence supports the use of formoterol 
as needed in all types and severities of asthma.There is a 
suggestion that, as well as improving asthma control, it 
could also result in a decrease in healthcare utilization. 
This hypothesis has still to be tested in large studies re- 
flecting true clinical practice. Many studies, with very 
specific inclusion and exclusion criteria, limit the type of 
patients included and it is not always possible to extrapo- 
late the results observed to the general population. The 
Real-Life Effectiveness of Oxis c~ Turbuhaler ~' 
(RELIEF) study is an ongoing trial designed to present a 
comprehensive picture of formoterol used as needed. 
This large, open, randomized, parallel-group study in 
18 000 patients across the world includes a broad range 
of patients and assesses the use of formoterol as needed 
in asthmatic patients over a 6-month period. Patients 6 
years or older, with a diagnosis of asthma, and requiring 
fl2-agonist therapy for relief of symptoms, were rando- 
mized to receive their usual maintenance treatment plus 
either formoterol 4.5#g or salbutamol 200#g, both as 
needed. Patients with concurrent conditions, other than 
pregnancy or lactation, will be included.The study design 
is shown in Fig. 2. 
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The study aims to  determine  the therapeut ic  outcome 
wi th  fo rmotero l  as needed in a real clinical sett ing and 
pat ient  populat ion,  i.e. the effectiveness of  fo rmotero l  
as first-~ine rel iever medicat ion.  The pr imary  clinical ob-  
ject ive is to  assess the safety of  fo rmotero l  as needed by 
mon i to r ing  serious adverse events and discontinuations 
of  therapy due to  adverse events. The secondary objec- 
t ive is to  compare the efficacy of  fo rmotero l  w i th  salbu- 
tamol  by mon i to r ing  t ime to  f i rs t  exacerbat ion,  which is 
def ined as hospital izat ion due to  deter io rat ing  asthma, 
emergency t reatment  due to  asthma, a requ i rement  for  
oral  steroids lasting at least 5 days or  a need to  increase 
maintenance therapy due to  worsen ing asthma. Other  
efficacy parameters  to  be col lected are: number  of  ex- 
acerbations; use of  as-needed medicat ion;  and number  
of  days w i th  asthma. The study wi l l  also include data on 
health economics including healthcare resource uti l iza- 
t ion and the number  of  days patients are incapable of  
conduct ing the i r  usual activit ies. 
CONCLUSIONS 
Current ly  available data suggest that  fo rmotero l  is an ef- 
fect ive and we l l - to le ra ted  t reatment  opt ion  in patients 
w i th  asthma, in both  as-needed and regular t reatment .  
The RELIEF study should help to  establish the place of 
fo rmotero l  in asthma management ,  u l t imately  leading 
to  the inclusion of  fo rmotero l  in t reatment  guidelines 
for  use as needed in all patients w i th  asthma. Formotero l  
has been shown to  be effective in asthma of  all severit ies 
and w i th  its fast onset  and long durat ion of  act ion pro-  
vides addit ional benefits compared w i th  o ther  /~2- 
agonists. It is wel l  to le ra ted  in high doses and suitable 
for  use in mildly asthmat ic  patients and in the t reatment  
of  acute attacks. Fur thermore ,  for  patients requir ing 
both  maintenance and rel iever therapy, fo rmotero l  could 
be used in both  circumstances, reducing the number  of  
inhalers necessary whi ls t  maintaining good 
asthma contro l .  
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